Impact Factor
3.61
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.84
294 total citations
h5-index
26
h5 depth signal
Cited share
78.7%
48 of 61
Total citations
294
Citation footprint
Metric signal
4.88
External metric anchor
Self-citation
4.1%
12 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
224
Netherlands
46
United Kingdom
43
Japan
30
Germany
25
Citing Fields of Research
Nucleic Acids Chemistry
233
Noncoding RNA
117
Drug Delivery Systems
48
Biosensors
36
Musculoskeletal Disorders
29
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
634
Articles tracked across the journal lifetime
Indexed publication set
61
48 cited publications
Last 12 months
34
3.1 publications/month
Open access share
11.8%
4 OA publications in the last year
Leading citing country
United States
224 citing publications
Leading citing field
Nucleic Acids Chemistry
233 citing publications
Latest tracked publication
15 October 2026
10 recent records available
Coverage & Indexing History
v21n3, 2011-
v21n3, 2011-
Research Focus & Classification
Indexed Subjects
Nucleic Acids Chemistry
Issuing & Sponsoring Bodies
Contributor
Oligonucleotide Therapeutics Society
Broad Categories
Biochemistry
Drug Therapy
Molecular Biology
Nucleic Acids Chemistry
MeSH Descriptors
Antisense Elements (Genetics)
Nucleic Acids
Oligonucleotides
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1177/21593337261496161
Open DOI
Nucleic Acid Therapeutics in an Age of Artificial Intelligence
Artificial intelligence (AI) is transforming how scientific hypotheses are formulated, tested, and applied. Nucleic acid therapeutics can benefit from emerging opportunities but will also face new challenges. AI lowers the barrier to hyp...
02
DOI 10.1177/21593337261494829
Open DOI
Antisense Oligonucleotides that Are Toxic to Prion-Infected Mice Share an Emergent Mechanism
Some, but not all, gapmer antisense oligonucleotides (ASOs) delivered into cerebrospinal fluid exhibit fatal subacute toxicity in late-stage prion-infected mice but not in uninfected mice. Here, we performed a battery of in vivo studies ...
03
DOI 10.1177/21593337261494828
Open DOI
Nonclinical Development of Oligonucleotide-Based Therapeutics: Insights from an IQ DruSafe ONT Working Group Survey
Oligonucleotide-based therapeutics (ONTs) present unique nonclinical development challenges that are not fully addressed by paradigms established for small molecule pharmaceuticals or biologic therapeutics. To better understand current i...
04
DOI 10.1177/21593337261488803
Open DOI
Incorporation of a pH-Sensitive Linker into Lipid–ASO Conjugates Drives Increased Endosomal Membrane Remodeling Events
Oligonucleotide therapeutics have great potential for the treatment of previously “undruggable” human diseases; however, their broad utility is limited by challenges in delivery and achieving sufficient endosomal escape. Systemic deliver...
05
DOI 10.1177/21593337261479163
Open DOI
rHuPH20 Enhances Extravascular Delivery of mRNA Lipid Nanoparticles in Mice and Minipigs
Extravascular administration of mRNA lipid nanoparticles (mRNA-LNPs) offers practical and clinical advantages but is limited by tissue barriers that restrict dispersion, lymphatic access, systemic exposure, and ultimately, target tissue ...
06
DOI 10.1177/21593337261476421
Open DOI
Embryo–Fetal Development and Maternal–Fetal Exposure of the Von Willebrand Factor Binding Aptamer Rondaptivon Pegol (BT200) in Rabbits
Rondaptivon pegol (BT200) is a PEGylated RNA aptamer that prolongs von Willebrand factor (VWF) and factor VIII half-lives in patients with hemophilia A and von Willebrand disease (VWD) type 2B. Embryo–fetal safety is particularly relevan...
07
DOI 10.1177/21593337261473518
Open DOI
Evaluation of Antisense Oligonucleotide-Associated Neuronal Lysosomal Changes
Antisense oligonucleotides (ASOs) are a rapidly growing therapeutic modality that directly modulate splicing or expression of disease-causing genes. ASOs are internalized through various endocytic mechanisms that converge on the endolyso...
08
DOI 10.1177/21593337261473078
Open DOI
Biodistribution of Phosphorothioate-Based Antisense Oligonucleotides in Stabilin Receptor Knock-Out Models
Phosphorothioate-based antisense oligonucleotides (PS-ASO) are a common class of ASO for therapeutic uses due to their resistance to nucleases and known deposition in human physiological systems. On the molecular level, these ASOs are re...
09
DOI 10.1177/21593337261469503
Open DOI
Optimized Chemical Modifications Enhance Lipid Nanoparticle-Mediated siRNA Silencing of YAP1 and WWTR1
Lipid nanoparticles (LNPs) are clinically validated carriers for the delivery of small interfering RNA (siRNA). Their efficient tissue accessibility and cellular uptake complement conjugated siRNA approaches. While chemical modifications...
10
DOI 10.1177/21593337261458148
Open DOI
Aptamers: Current Applications in Leukemia Diagnostics and Therapeutics
Aptamers are single-stranded synthetic oligonucleotides that bind noncovalently to targets with high affinity and selectivity. They are generated through an in vitro selection process known as Systematic Evolution of Ligands by Exponenti...
Bibliographical & Catalog Notes
Also issued online.